Read publication

Welcome to the April 2017 edition of our newsletter. The EMEA Healthcare Industry Group Newsletter is your regular digest of legal developments affecting the life science and healthcare industries across the region.

In This Issue

European Union

  • Biosimilars: What should doctors consider before making switching decisions?
  • New EU medical devices regulations require Medtech companies to look at supply chain contracts
  • The New MedTech Europe Code of Ethical Business Practice
  • Brexit - Healthcare Update
  • Competition Update: European Commission's new ‘innovation competition’ theory of harm
  • ECJ recognises liability of notified bodies for damages resulting from defective medical devices
  • The European Medicines Agency launches a pilot project to provide tailored scientific advice for the development path of biosimilars


  • The unpacking of drugs for the preparation of galenic medicines also by private pharmacies is legitimate
  • The Government published a draft Legislative Decree providing corrective measures to the Public Procurement Code
  • Farmaindustria publishes the data on the time for the refund of drugs and medical devices by the NHS


  • New Fenin Code Developments


  • Changes to Clinical Research Process announced
  • New Standards for Medical Waste Control
  • Turkey Crackdown on Unsafe and Non-Compliant Medical Devices and Cosmetics Products
  • Turkey Revises Pricing Rules on Medicinal Products for Human Use
  • TÄ°TCK Changes to certification process for Cosmetics


  • Baker McKenzie elected as a Legal Partner of the EBA Healthcare Committee
  • Reference pricing and reimbursement of pharmaceuticals
  • Changes in the state regulation of prices for medical devices
  • Draft strategy on implementing the state pharmaceuticals policy for 2017-2025
Explore More Insight